Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer

IMPORTANCE: Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment’s cost justifies its benefits ha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Sherman, Scott K., Lange, Joel J., Dahdaleh, Fadi S., Rajeev, Rahul, Gamblin, T. Clark, Polite, Blase N., Turaga, Kiran K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2018
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440196/
https://ncbi.nlm.nih.gov/pubmed/30489611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5070
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia